ErbB1, or Epidermal Growth Factor Receptor (EGFR), is consistently overexpressed and occasionally mutated and amplified in head and neck squamous cell carcinomas [13,18,19] and is an established target of monoclonal antibody (mAb) therapies with a meaningful clinical impact [12]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.